10x Genomics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
10x Genomics reported Q2 2026 revenue of $151.0M (vs. $172.9M in Q2 2025), a 12.7% decline nominally but +3% organically excluding patent settlement revenue. The company posted a net loss of $17.9M vs. net income of $34.5M in Q2 2025, primarily due to a $40.7M settlement gain in the prior year that didn't recur. The company raised full-year 2026 revenue guidance to $610–$630M (previously $600–$625M), representing 2–5% organic growth. Gross margin improved to 74% from 72%, driven by lower manufacturing costs and tariff refunds. The company acquired Proteintech Genomics division and announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital.
Why this rating
Modest organic growth (+3%) and guidance raise are positive, but net loss swing and declining U.S. revenue (-20.5%) offset gains. Event is ~2–3% of company market cap; material but not trajectory-altering.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.